CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

Importance The safety and efficacy of bivalirudin compared with heparin with or without
glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing …

Objectives: This multicenter pragmatic investigation assessed outcomes following clinical
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …

The success of trials that have shown net clinical benefits of antithrombotic drugs as well as
the increasing prevalence of cardiovascular diseases in an ageing population have led to …

Despite advancements in treatments for acute coronary syndromes over the last 10 years,
they continue to be life-threatening disorders. Currently, the standard of treatment includes …

CYP2C19 genotype‐guided antiplatelet therapy following percutaneous coronary
intervention is increasingly implemented in clinical practice. However, challenges such as …

There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are
used to prevent ischemic outcomes in common diseases such as coronary and peripheral …

ABSTRACT Introduction Various pharmacogenomic (PGx) variants differ widely in different
ethnicities. and clinical outcomes associated with these variants may also be substantially …

Current guidelines recommend dual antiplatelet therapy—a P2Y12 inhibitor (clopidogrel,
prasugrel, or ticagrelor) and aspirin—for patients undergoing percutaneous coronary …